Antipsoriatics (A61P17/06)

A   Human necessities(308602)
A61P17        Drugs for dermatological disorders(1612)
A61P17/06                     Antipsoriatics(181)
External application means for chronic dermatosis treatment, and method for its production // 2628535
FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex

ethods of production isoquinolinones and solid forms isoquinolinones // 2626883
FIELD: chemistry.SUBSTANCE: invention relates to new polymorphic forms of the compounds of formula (I), having inhibitory action against phosphoinositide 3-kinase (PI3K). The compounds may be used to treat cancer, such as leukemia, lymphoma, inflammatory disease and autoimmune disease. The polymorphic forms of the compound of formula (I) is the polymorphic form C of the hydrate of the compound of formula (I), which has characteristic peaks in the x-ray powder diffraction pattern (XRPD) 2θ=10.4°(±0.2°), 13.3°(±0.2°) and 24.3°(±0.2°); Polymorph A, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 12.2°(±0.2°), and 18.3°(±0.2°); Polymorph B, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=7.9°(±0.2°), 13.4°(±0.2°), and 23.4°(±0.2°); polymorphic form D, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=11.4°(±0.2°), 17.4°(±0.2°), and 22.9°(±0.2°); polymorphic form E, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=6.7°(±0.2°), 9.3°(±0.2°) and 24.4°(±0.2°); Polymorphic form F, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 17.3°(±0.2°), and 24.6°(±0.2°); Polymorphic form G which is the solvate of the tert-butyl methyl ether of the compound of formula (I) and has characteristic peaks in the powder XRPD pattern 2θ=6.7°(±0.2°), 9.5°(±0.2°) and 19.0°(±0.2°); Polymorphic form H, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=8.9°(±0.2°), 9.2°(±0.2°) and 14.1°(±0.2°); Polymorphic Form I, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.7°(±0.2°), 19.3°(±0.2°), and 24.5°(±0.2°), and the polymorphic form J, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.1°(±0.2°), 17.3°(±0.2°) and 18.3°(±0.2°). The invention also relates to a process of preparing form C. For example, mentioned process comprising (i) exposure of the medium containing water, a composition comprising at least one polymorphic form, not a form of a compound of formula (I), for a period time sufficient for the transformation, preferably for 18-24 hours, at least 50% of the total amount of the polymorphic form (s) a non-form C; and (ii) recovering mentioned polymorph form C.EFFECT: high effectiveness of compounds.84 cl, 31 dwg, 16 tbl, 42 ex
Furo[3,2-b]- and thieno[3,2-b]pyridine derivatives as tbk1 and ikkε inhibitors // 2622034
FIELD: pharmacology.SUBSTANCE: invention relates to a novel compound of formula I , wherein X means O or S, R1 means O(CYY)nHet1 or O(CYY)nCyc, R2 means Ar or Het2, Het1 means pyrrolidinyl, tetrahydro imidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyrimidinyl, azepanyl, tetrahydrofuranyl, furyl, thienyl, pyrazolyl, pyridyl, chromanyl or piperazinyl, each of which is unsubstituted or monosubstituted by A, COOA, OY and/or =O (carbonyl oxygen), Het2 means mono- or bicyclic saturated, unsaturated or aromatic heterocycle which contains from 1 to 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted by A, (CYY)p-OY, (CYY)p-Het1, -CO-Het1 and/or =O, Ar means phenyl, which is unsubstituted or monosubstituted by Hal, A, (CYY)p-OY, (CYY)p-Het1, (CYY)p-COOY, CO(CYY)pNH2, CO-NYA, CONY(CYY)mNYCOOA, CO-Het1, O(CYY)p-NYY, CONY(CYY)pHet1 and/or CONH(CYY)pNHCOA, Y means H or an alkyl, which contains 1, 2, 3 or 4 C-atom, A is an unbranched or branched alkyl that contains from 1 to 10 C-atoms, Cyc means a cycloalkyl, which contains from 3 to 7 C-atoms, which is unsubstituted or monosubstituted by A, Hal means F, Cl, Br or I, n means 0, 1 or 2, m means 1, 2 or 3, p means 0, 1, 2, 3, or 4 and pharmaceutically applicable salts and stereoisomers thereof, including mixtures thereof in all ratios.EFFECT: compounds are inhibitors of TVK1 and ε IKK, and can be used in particular for the treatment of malignant neoplasms and inflammatory diseases.6 cl, 3 tbl, 120 ex
Pyrazole quinolinone derivatives, their preparation and therapeutic application // 2621037
FIELD: pharmacy.SUBSTANCE: invention relates to compounds according to formula (I) , wherein R1, R2 and R3 are as defined in claim cl. 1. The compounds of this invention are reversible and selective inhibitors of type 2 methionine aminopeptidase (MetAP2). The invention also relates to intermediates for preparing the compounds of formula (I), drug and pharmaceutical compositions based on the compounds of formula (I) and their therapeutic application.EFFECT: increased efficiency of compounds application.24 cl, 2 tbl, 25 ex
ethod for treatment of heavy forms of psoriasis // 2620552
FIELD: medicine.SUBSTANCE: complex treatment is performed, including introduction of drugs to improve microcirculation, desensitizing and de-intoxication means, local therapy and introduction of stemokin immunomodulator. Stemokin is injected intramuscularly, 1 ml of solution for 7 days, a two-day break is made, the course of treatment is repeated. Next, stemokin is injected intramuscularly in the form of spray into each nasal passage 2 times a week for 2 months.EFFECT: achievement of a pronounced clinical remission and lengthening of the inter-recessive period.10 tbl, 1 ex
Bacteriorhodopsin application as cosmetic and/or therapeutic agent for complex treatment of dermatoses // 2617425
FIELD: medicine.SUBSTANCE: invention is the use of an aqueous solution of Halobacterium salinarum VKPM B-11850 halophilic bacteria strain bacteriorhodopsin comprising bacteriorhodopsin in a concentration of 0.24-0.75%, as a cosmetic agent for skin care, or as a therapeutic agent for the combined treatment of dermatoses.EFFECT: expansion of the arsenal of means for skin care and comprehensive treatment of dermatoses.2 cl, 4 ex
Cosmetic composition of fluid formed during hatching fish roe // 2611639
FIELD: cosmetics.SUBSTANCE: invention refers to cosmetic and pharmaceutical industry and represents a method for producing a cosmetic composition of fluid formed during the hatching of fish roe, including at least the following steps: (a) suspending of fish roe in minimal volume of water; (b) induction of synchronized fast hatching said caviar, preferably so, that hatching is terminated for less than 6 hours for more than 80% of embryos; (c) filtration of liquid, formed at hatching, from step (b) to obtain a composition, note here that said fluid filtration stage, formed at hatching includes a liquid filter formed at hatching, using a filter with pore size of at least 5 mcm and collecting of the filtrate; (d) treating the filtrate from stage (c) by means of ion-exchange chromatography, including: (1) loading of the filtrate to ion-exchange column, preferably on DEAE (diethylaminoethylic) column; (2) washing the column by suitable buffer, preferably buffered by irrigating solution with pH 7–9; (3) elution of column leucolectin polypeptides using first elution buffer or solvent, note here that preferably the first elution buffer comprises buffered flushing solution, additionally contains salt in concentration of 50 to 100 mM; (4) elution from column of remaining polypeptides using second elution buffer or solvent, at that, preferably second elution buffer comprises buffered flushing solution, containing salt in concentration of 500 mM to 2 M; (5) collecting eluate from step (4); (e) replacement of water in the eluate from step (5) on a cosmetically acceptable buffer; (f) filtering the solution obtained at step (e), using a filter with pore size of 0.15–0.30 mcm and collecting the filtrate; and (g) preparation of said cosmetic composition from the filtrate obtained at step (f).EFFECT: invention provides effective skin moistening and pilling of the stratum corneum.25 cl, 7 dwg, 1 tbl, 6 ex
Use of preparation laennek for treating a disease, associated with impaired immunity, which is a chronic recurrent herpes, atopic dermatitis or psoriasis // 2599038
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely dermatology and immunology. Use of Laennek as immunotropic preparation is disclosed for treating a disease, associated with impaired immunity, which is chronic recurrent herpes, atopic dermatitis or psoriasis, by drop intravenous introduction of Laennek 2 times a week in an amount of 10 procedures during integrated therapy, where the first drop introduction to patient is 4.0 ml Laennek dissolved in 200-250 ml of saline solution (0.9 % aqueous solution of sodium chloride) through ulnar vein for 1 hour 20 minutes, second and subsequent introduction contain 10.0 ml of Laennek dissolved in 250 ml of 0.9 % saline solution through ulnar vein for 1.5 hours.EFFECT: use of Laennek as immunotropic preparation is disclosed for treating a disease, associated with impaired immunity, which is chronic recurrent herpes, atopic dermatitis or psoriasis.1 cl, 3 ex

ethods of treating psoriasis using il-17 antagonists // 2591083
FIELD: medicine.SUBSTANCE: for treating psoriasis an anti-IL-17 antibody is administered in effective doses in accordance with developed scheme of administration.EFFECT: group of inventions provides effective treatment of psoriasis, including its recurrences, without aggravation of disease.18 cl, 11 dwg, 11 tbl, 6 ex

onoclonal antibodies against interleukin-31 // 2588462
FIELD: biotechnologies.SUBSTANCE: invention relates to biotechnology. Disclosed is an isolated antibody that specifically binds to at least one of canine interleukin-31 (IL-31), or feline IL-31. Such antibodies may be in form of diagnostic and/or veterinary compositions useful for treatment accompanied by itching and/or allergic condition in dogs or cats.EFFECT: invention widens range of treatments for animals.27 cl, 23 dwg, 5 tbl, 12 ex

Fatty acid fumarate derivatives and uses thereof // 2588256
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, enantiomers or stereoisomers; in which values for groups W1, W2, R3, L, Z, a, b, m, c, d, etc. are defined in patent claim.EFFECT: invention also refers to pharmaceutical compositions based on said compounds possessing inhibitory activity on NF-kB, for treating inflammation or inflammatory disease, type II diabetes, insulin-resistant cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dislipidemia, retinopathy, neuropathy, macular edema, diabetic nephropathy, IgA nephropathy, CLD, inflammatory diseases of kidneys.25 cl, 4 dwg, 25 ex, 1 tbl

Preparation from eggs with regenerative, analgesic and anti-inflammatory properties // 2585049
FIELD: medicine.SUBSTANCE: invention relates to a preparation containing fertilised eggs, a method of its preparation and application. Preparation of eggs includes a mixture of yolk and protein extracted from fertilised eggs, incubated for a period of time from 18 to 36 hours. Said mixture of yolk and protein is characterised by such ratio, in compliance with which protein content is equal to 2 vol% to 40 vol%. Method for producing preparation of eggs involves incubation of fertilised eggs for a period of time from 18 hours to 36 hours; selection of certain amount of yolk and a certain amount of protein from incubated fertilised eggs obtained at previous step, in such proportion that protein quantity ranges from 2 vol% to 40 vol% of volume of yolk; homogenised yolk and protein and sharp cooling of preparation of eggs. Invention also discloses a functional food product, a dietary supplement, pharmaceutical, veterinary and cosmetic composition containing said preparation of eggs. Disclosed is use of said preparation of eggs as a cosmetic agent for skin care, as well as hair or fur. Also disclosed is use of preparation of eggs for preparing a drug for treating acute or chronic pain in case of conditions associated with pain; for treating degenerative diseases and conditions associated with inflammation.EFFECT: invention enables to obtain a preparation of eggs with high regenerative, analgesic and anti-inflammatory properties.19 cl, 12 dwg, 11 ex

Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists // 2573828
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new aminoalkylpyrimidine derivatives of formula (I) or their pharmaceutically acceptable salts exhibiting the properties of histamine H4 receptor antagonists. The compounds are applicable in respiratory diseases, including asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD); ophthalmic diseases, including conjunctivitis, dry eye syndrome, cataract; dermatological diseases, including eczema, dermatitis (e.g., atopic dermatitis), psoriasis, urticaria, pemphigus, dermatitis herpetiformis, cutaneous vasculitis, itch; inflammatory intestinal diseases, including nonspecific ulcerative colitis, Crohn's disease; and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, cutaneous lupus, systemic lupus erythematosus, widespread vasculitis and graft rejection. In formula IR1 and R2 form together with N atom to which they are bound, a saturated heterocyclic group containing one nitrogen atom and free frpm any other heteroatoms; the above heterocyclic group is substituted by one -NRaRb group and optionally substituted by one or more C1-4alkyl groups; wherein the heterocyclic group represents a 4-7-merous monocyclic group; Ra represents H or C1-4alkyl; Rb represents H or C1-4alkyl; R3 represents H or C1-8alkyl; R4 represents a) C1-8alkyl optionally substituted by one or more halogens; b) C3-10cycloalkyl-C0-4alkyl; c) aryl-C0-4alkyl or d) 5-6-merous heteroaryl-C0-4alkyl, wherein the radicals b), c) or d) may be substituted as specified in the patent claim; n equals to 1 or 2; each R5 independently represents H or C1-8alkyl.EFFECT: compounds can find application in treating or preventing an allergic, immune system or inflammatory disease, pain or cancer.22 cl, 18 ex

Novel heterocycles // 2572616
FIELD: medicine.SUBSTANCE: invention relates to application of formula (I) compound, for preparation of medication, used for treatment of chronic obstructive pulmonary disease. In compound (I) A represents aryl group, selected from phenyl; B represents aryl group, selected from phenyl or pyridyl; X represents carbon atom or nitrogen atom; R represents substituted or non-substituted groups, selected from heteroaryl groups, including pyridyl, thienyl, furyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl and pyrazinyl, and heterocyclic groups, including morpholine, thiomorpholine, piperazine, piperidine, piperidin-4-one, pyrrolidine, pyrrole-2,5-dione, thiazolidine, 1-oxido-thiazolidine and 1,1-dioxido-1,3-thiazolidine; where heterocyclic group is optionally substituted with substituents, independently selected from substituted or non-substituted (C6)aryl, -CH2-C6aryl, -CH2-heteroaryl, CO-C6aryl, -CO-heteroaryl, -CS-heteroaryl, -CO-C3-6cycloalkyl, cyano(C1-4)alkyl, -O-methyloxime, -SO2Cl, formyl, or other substituted or non-substituted heterocyclic group, selected from pyridyl, pyrimidinyl and piperidinyl; where binding of heterocyclic group to pyrimidine ring takes place through carbon or nitrogen atom; and where group R or substituent of heterocyclic group R are optionally substituted. Other substituents are given in invention formula.EFFECT: compounds are suitable for treatment of immunological diseases, inflammation, pain impairment, rheumatoid arthritis; osteoporosis, multiple myeloma, uveitis, acute and chronic myelogenous leukaemia; atherosclerosis, cancer, cachexia and other diseases.15 cl, 15 tbl, 158 ex
Cosmetic or dermatological composition for local application // 2571491
FIELD: medicine.SUBSTANCE: as main natural active ingredient compositions contain rhizome of black cohosh (Rhizoma cimicifugae racemosae) for prevention and treatment of skin diseases, selected from acne, seborrhoea, atopic eczema (neurodermatitis), hirsutism, psoriasis and dry/allergy-predisposed skin in people, as well as additional auxiliary agents and/or additives. Application of dermatological composition for prevention and treatment of skin diseases. Pharmaceutical medication, containing dermatological composition.EFFECT: increased efficiency of prophylaxis and treatment of skin diseases.12 cl, 1 ex

New therapeutic methods for using inecalcitol // 2571490
FIELD: medicine, pharmaceutics.SUBSTANCE: what is presented is using inecalcitol for treating and/or preventing rachitis, osteoporosis, osteomalatia, psoriasis, autoimmune diseases, such as multiple sclerosis, type I diabetes mellitus, hyperparathyroid, benign prostate hyperplasia, any kinds of cancer in doses containing from 1.5 mg/day to 4 mg at intervals specified in: every second day, once a day or twice a day.EFFECT: treating the patients suffering hormone resistant prostate cancer with inecalcitol, which implies no inadmissible toxicity or disease progression has been shown.10 cl, 4 dwg

Pharmaceutical formulations containing corticosteroids for topical application // 2568598
FIELD: medicine, pharmaceutics.SUBSTANCE: pharmaceutical composition for topical skin application contains corticosteroid representing halobetasol propionate in the concentration of less than 0.5% and a liquid oily component containing one or more esters of monocarboxylic and dicarboxylic acids. Esters of dicarboxylic acids are specified in a group consisting of diethylsebacate and diisopropyladipate. Esters of monocarboxylic acids are specified in a group consisting of isopropylmyristate and isopropylpalmitate. The concentration of the above liquid oily component makes from 1.5 to 3 times required to dissolve the amount of the corticosteroid in the composition at temperature 22°C±2°C completely, whereas the concentration of the esters in the liquid oily component makes at least 10% of the concentrations of the liquid oily component in the composition. What is also described is a method of treating a skin disorder.EFFECT: invention provides reducing side effects of using halobetasol.21 cl, 7 tbl, 5 ex

Tofa analogues, applicable in treatment of dermatological disorders or conditions // 2561729
FIELD: medicine, pharmaceutics.SUBSTANCE: invention describes analogues of 5-(tetradecyloxy)-2-furoic acid (TOFA) of formula , where R1 represents -O-R2, R2 independently represents heterocyclylalkyl or halogenalkyl; or R1 represents -O-R3-C(O)N(R5)R6, each R3 represents alkylene chain and R4 represents optionally substituted alkyl or optionally substituted phenyl, each R5 independently represents hydrogen, alkyl or cycloalkyl and each R6 represents alkyl, cycloalkyl, benzyl or -R3-C(O)OR4; or any R5 and R6 together with nitrogen atom, which they are both bound to, form optionally substituted N-heterocyclyl, or its pharmaceutically acceptable salts.EFFECT: invention relates to pharmaceutical compositions for treatment of dermatological disorders or conditions, characterised by hyperactivity of sebaceous glands, such as acne and greasy skin, and other dermatological disorders and conditions, containing TOFA analogues and pharmaceutically acceptable excipient for dermatological or peroral introduction.24 cl, 3 dwg, 6 tbl, 33 ex

Pharmaceutical composition, including dissolving mixture and vitamin d derivative or analogue // 2559084
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed is stable in storage water-free composition for local treatment of psoriasis by application on skin, including homogeneous mixture of therapeutically effective quantity of calcipotriol in dissolved form; dissolving mixture, consisting of solvent based on fatty acid triglycerides, auxiliary solvent, selected from polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether, polyoxypropylene-3-myristyl ether, polyoxypropylene-5-ceteth 20; and lipophilic penetration enhancer, selected from N-alkylpiperidone, N-alkylpyrrolidone, such as N-methylpyrrolodone, N-hydroxyalkylpyrrolidone or 2-pyrrolidone; where ratio of solvent, auxiliary solvent and penetration enhancer is in range from 50:25:25 to 75:10:15; and where said dissolving mixture is included into composition in amount, sufficient for effective calcipotriol dissolution, and water-free pharmaceutically acceptable carrier, including at least one paraffin.EFFECT: technical result consists in chemical stability of calcipotriol with absence of skin irritation.21 cl, 2 dwg, 5 tbl, 7 ex

ethod of treating dermatosis and detoxication agent for implementing it // 2558827
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to dermatology, and describes a method of treating dermatosis based on patient's detoxication by binding toxins with using enterosorbents and discharge them. The method involves dissolving toxins and stimulating diuresis with using an infusion therapy, administering normal saline, administering a diuretic which is presented by lasix, stimulating the blood microcirculation, including at the level of small vessels with using Fraxiparine, low-molecular heparin, with the agent nadroparin calcium; the enterosorbent is Polysorb.EFFECT: method enables increasing the clinical effectiveness for dermatosis by the smooth effect of the homeostasis system and detoxification, reducing the body intoxication, dehydration and hypercoagulation, improving the small microcirculation and can be used in treating severe forms of chronic dermatosis and psoriasis.6 cl, 1 tbl, 1 dwg, 2 ex

ethylhydrofumarate prodrugs, pharmaceutical compositions containing them and methods for using // 2554347
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.47 cl, 1 tbl, 54 ex

N-containing heteroaryl derivatives as jak3 kinase inhibitors // 2553681
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.EFFECT: obtaining novel heteroaryl derivatives.27 cl, 41 ex

Quinoline-like compound substituted by phosphorus-containing group, method for preparing it, therapeutic composition containing this compound and using it // 2551274
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.20 cl, 42 ex, 8 tbl, 3 dwg

Novel crystalline forms of n-[-2[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azatidine-sulphonamide // 2548044
FIELD: chemistry.SUBSTANCE: invention relates to a novel crystalline form of N-[-2[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azatidine-sulphonamide, which has an X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1.5418 E and containing, at least, one crystalline peak with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 2 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 3 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1. The said crystalline form can contain additional crystalline peaks with a value 2-theta (in degrees), selected from 12.9 and 18.0, obtained under the said conditions.EFFECT: crystalline form has the X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1,5418 E, with the crystalline peaks with a value 2-theta (in degrees) 12,9, 13,1, 18,0, 21,0, 22,5, 25,1, 25,3, 28,8, 29,1 and 30,4, and has melting point (beginning) 152,7°C.6 cl, 3 dwg, 2 tbl, 5 ex

New therapeutic agents for local administration based on sulphated hyaluronic acid as cytokine activity stimulators or inhibitors // 2543354
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.8 cl, 33 ex, 15 dwg, 3 tbl

Oestrogen receptor ligands and methods of using them // 2543339
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, namely urology, and can be used for treating advanced prostate cancer in male individuals. That is ensured by administering a therapeutically effective amount of a compound of formula IV or its isomer, a pharmaceutically acceptable salt, a pharmaceutical product, a polymorph, a hydrate or any combination thereof.EFFECT: method provides treating effectively, inhibiting, reducing an incidence, relieving a severity or inhibiting advanced prostate cancer, as well as conducting the palliative treatment of advanced prostate cancer.12 cl, 21 ex, 20 tbl, 23 dwg

Using alpha 2 adrenergic receptor agonists for treating or preventing psoriasis // 2538729
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and represents a method of treating psoriasis or a related symptoms, in an individual, involving the local administration of a local composition containing a therapeutic effective amount of an α2 adrenergic receptor agonist and a pharmaceutically acceptable carrier on an individual's skin area, wherein the skin area is subject to psoriasis or the related symptom, or prone thereto, and wherein the α2 adrenergic receptor agonist is brimonidine.EFFECT: invention provides developing the effective and safe method for treating or preventing psoriasis with no side effects or small side effects.10 cl, 1 tbl, 2 ex

Compositions containing berberine or its analogues for treating skin diseases related to rosacea or blush // 2533458
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry and represents a local pharmaceutical composition for treating rosacea containing at least 0.02% berberine or a biologically equivalent berberine analogue, such as palmatine, and an ingredient specified in a group consisting of water, methanol, ethanol and dimethylsulphoxide, wherein berberine or the biologically equivalent berberine analogue represents the major pharmaceutically active ingredient.EFFECT: invention provides extending the range of products for treating rosacea.4 cl, 6 ex, 2 dwg

Stabilised composition for treating psoriasis // 2526162
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and describes a non-aqueous ointment containing a compound of vitamin D, corticosteroid and ester of N,N-di(C1-C8)alkylamino-substituted (C4-C18)alkyl(C2-C18)carboxylic acid in Vaseline, optionally containing mineral oil and tocopherol.EFFECT: ointment is characterised by storage stability and high skin penetration of the corticosteroid.23 cl, 4 dwg, 5 tbl, 3 ex

Cyclosporine derivatives for treating ophthalmic and skin diseases and conditions // 2521358
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound selected from a group consisting of compounds presented by formula:In the above formula, R1 represents S-Alk-R, wherein Alk represents methylene, C2-C6 polymethylene bond or C3-C6 alkenylene bond, R represents -N=C(NR3R4)(NR5R6) or -NR7[(NR3R4)C=NR5], or -N=C(R8)(NR9R10), wherein R3-R10 represents H, Alk, Ar or (CH2)nAr, wherein Ar represents an aryl group, and n represents an integer from 1 to 13, or R3 and R4, or R4 and R5, or R5 and R7, or R3 and R7, or R9 and R10, or R8 and R9 together can represent -(CH2)x-, wherein x represents an integer from 2 to 5, and R2 is specified in a group consisting of hydroxyl, alkyl having from 1 to 7 carbon atoms, and substituted by alkyl hydroxyl having from 1 to 7 carbon atoms.EFFECT: preparing new cyclosporine derivatives.5 cl, 2 ex
ode of dosing selective s1p1 receptor agonist // 2519660
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed are: application of (R)-5-[3-chloro-4-(2,3-dihydroxypropoxy)benz[2]ylidene]-2-([2]-propylimino)-3-ortho-tolylthiazolidin-4-one (compound 1) or its salt for obtaining a medication for prevention and/or treatment of a disease or disorder, associated with the immune system activation, where the medication represents a set of Compound 1 doses; with the dose inducing the heart desensitisation in an initial phase of treatment and being lower than the final dose; with the said initial phase of treatment the dose is introduced with a frequency ensuring support of the heart desensitisation until the next acute reduction of heart rate occurs, after which the dose is titrated with increase to the final dose of Compound 1; a corresponding method of treatment and the set of doses.EFFECT: invention ensures reduction and minimisation of undesirable side effects of Compound 1 (acute reduction of heart rate, atrioventricular conduction, or fatigue and dizziness) aimed at increase of Compound 1 tolerance and safety, as well as minimises problems, associated with monitoring at the initial phase of treatment or after interruption of treatment in the period of repeated treatment.22 cl, 1 tbl
Extract from aboveground parts of oat grown before ear formation // 2517346
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, in particular to a composition, possessing immunomodulating and anti-inflammatory properties. The dermatological composition, possessing immunomodulating and anti-inflammatory properties, as an active ingredient, contains an extract of the aboveground part/parts of oat, collected before ear formation. The cosmetic composition, possessing immunomodulating and anti-inflammatory properties. Application of the extract of the aboveground part/parts of oat, collected before ear formation, possessing immunomodulating and anti-inflammatory properties, as a medication.EFFECT: composition and extract possess expressed immunomodulating and anti-inflammatory properties.15 cl, 1 tbl, 3 ex

Phenoxypyridinylamide derivatives, and their use in treatment of pde4-mediated disease states // 2509077
FIELD: biotechnologies.SUBSTANCE: invention refers to a compound of formula (I): , where R1 represents NR7C(O)R8 or NR9R10; R2 represents hydrogen; R3 represents halogen; R4 represents hydrogen, halogen, cyano, hydroxy, C1-4alkyl, C1-4alkoxy, CF3, OCF3, C1-4alkylthio, S(O)(C1-4alkyl), S(O)2(C1-4alkyl), CO2H or CO2(C1-4alkyl); R5 represents C1-6alkyl (replaced with NR11R12 or heterocyclyl that represents nonaromatic 5-7-membered ring containing 1 or 2 heteroatoms independently chosen from a group containing nitrogen, oxygen or sulphur); R6 represents hydrogen, halogen, hydroxy, C1-4alkoxy, CO2H or C1-6alkyl (possibly replaced with NR15R16 group, morpholinyl or thiomorpholinyl); R7 represents hydrogen; R8 represents C3-6cycloalkyl (possibly replaced with NR24R25 group), phenyl or heteroaryl, which represents aromatic 5- or 6-membered ring containing 1 to 3 heteroatoms independently chosen from the group containing nitrogen, oxygen and sulphur, and which is probably condensed with one 6-membered aromatic or nonaromatic carbocyclic ring or with one 6-membered aromatic heterocyclic ring, where the above 6-membered aromatic heterocyclic ring includes 1 to 3 heteroatoms independently chosen from a group containing nitrogen, oxygen and sulphur; R9 represents hydrogen or C1-6alkyl (possibly replaced with pyrazolyl); R10 represents C1-6alkyl (possibly replaced with phenyl or heteroaryl group, which represents aromatic 5- or 6-membered ring containing 1 or 2 heteroatoms independently chosen from the group containing nitrogen, oxygen or sulphur, and which is possibly condensed with one 6-membered heterocyclic ring, where the above 6-membered aromatic heterocyclic ring contains 1 or 2 heteroatoms independently chosen from the group containing nitrogen, oxygen or sulphur; where the above phenyl and heteroaryl groups in R8, R9 and R10 are possibly independently replaced with the following group: halogen, hydroxy, C(O)R42, C1-6alkyl, C1-6hydroxyalkyl, C1-6halogenoalkyl, C1-6alkoxy(C1-6)alkyl or C3-10cycloalkyl; unless otherwise stated, heterocyclyl is possibly replaced with group of C1-6alkyl, (C1-6alkyl)OH, (C1-6alkyl)C(O)NR51R52 or pyrrolidinyl; R42 represents C1-6alkyl; R12, R15 and R25 independently represent C1-6alkyl (possibly replaced with hydroxy or NR55R56 group); R11, R16, R24, R51, R52, R55 and R56 independently represent hydrogen or C1-6alkyl; or to its pharmaceutically acceptable salts.EFFECT: new compounds are obtained, which can be used in medicine for treatment of PDE4-mediated disease state.10 cl, 2 tbl, 202 ex

Interleukin-15 antagonist peptide // 2506270
FIELD: chemistry.SUBSTANCE: invention relates to molecular pharmacology and particularly to a peptide which is an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound. The invention shows that when bound with an alpha subunit of the receptor (IL-15Rα) the peptide inhibits T cell proliferation induced by IL-15, tumour necrosis factor α (TNFα) induction caused by IL-15, and expression of IL-8 and IL-6 caused by IL-15Rα. The invention also relates to use of the peptide in treating pathologies where anomalous expression of IL-15 or IL-15Rα is associated with the course of a disease such as rheumatoid arthritis (AR) and prostate cancer.EFFECT: obtaining an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound.18 cl, 6 dwg, 6 ex
ethod of treating localised forms of psoriasis // 2501563
FIELD: medicine, pharmaceutics.SUBSTANCE: method relates to medicine, particularly to dermatology, and may be used in treating localised forms of psoriasis. That is ensured by administering 1% glutoxim 0.1 ml along the perimetre of a psoriasis patch at 1.0-1.5 cm once a day for 7-12 procedures.EFFECT: effective treatment ensured by no side effects, and reduced length of treatment.2 ex, 1 tbl
ethod of treating psoriasis // 2500443
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely - to dermatology. A method involves the ointment application and the ultrasound exposure. The ointment is methylprednisolone aceponate. The ultrasound exposure has an intensity of 0.7-1.0 Wt/cm2. The exposure length is 2-5 minutes per one field. The duration of a procedure is 12 minutes. The therapeutic course is 7 procedures.EFFECT: method reduces the side effects and complications provides achieving the immediate clinical effect and prolongs the remission length.1 tbl, 2 ex

ethod of treating psoriasis (versions) // 2497545
FIELD: medicine.SUBSTANCE: invention refers to a method of treating psoriasis by introducing an antibody or an antigen-binding determinant thereof able to bind to the IL-12 and/or IL-23 subunit p40 in a dose of approximately 0.1 5.0 mg/kg under therapeutic regimen into an individual. The antibody or antigen-binding determinant thereof can be introduced once every two weeks, once a week or once in various doses depending on the patient's state. The method is applicable for treating chronic psoriasis. The therapeutic course is cyclic; each cycle makes at least 12 weeks, i.e. the first long-term cycle which involves introducing the antibody; then the introduction of the antibody or determinant thereof is terminated for at least 12 weeks that is followed by another long-term cycle of at least 12 weeks that involves introducing the antibody or fragment thereof. A dose of the antibody or determinant thereof to be introduced makes approximately 100 mg to 200 mg. The treatment is controlled by a psoriasis area and severity index (PASI).EFFECT: using the method enables higher clinical effectiveness in chronic psoriasis.40 cl, 35 dwg, 12 tbl, 8 ex
ethod of treating psoriatic erythroderma // 2496498
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating the patients with psoriatic erythroderma. For this purpose, detoxification hormone therapy combined with external ointment therapy is preceded by prescribing Galavit in a therapeutic dose of 100 mg intramuscularly every day within the course of 10 procedures.EFFECT: method provides higher clinical effectiveness ensured by a shorter length of therapy, no side effects and prolonged remission.2 ex, 1 tbl

Softening composition // 2493834
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to cosmetic industry and represents dermatological composition, which as active ingredient contains combination of glycerol, vaseline and vaseline oil in form of emulsion of oil-in-water or water-in-oil type, where vaseline has temperature of dropping from 51°C to 57°C, consistence from 175 1/10 mm to 195 1/10 mm (conic penetration at 25°C) and viscosity from 4 cSt to 5 cSt at 100°C.EFFECT: invention ensures improvement of stability in storage and treatment of small superficial burns and exacerbation of eczematous process.23 cl, 3 ex, 1 tbl, 1 dwg

Emollient composition for preventive effect in atopic dermatitis // 2492856
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a composition for local application containing a combination of glycerol, Vaseline and Vaseline oil as an active ingredient presented in the form of an oil-in-water or water-in-oil emulsion to be used in preventing atopic dermatitis.EFFECT: invention provides preventing the onset of atopic dermatitis.24 cl, 3 ex, 1 tbl

Nanoemulsion // 2491917
FIELD: medicine.SUBSTANCE: group of inventions refers to a nanoemulsion for active agent delivery, a method for preparing it, compositions containing it, and to using a nanoemulsion for preparing pharmaceutical compositions for local application and cosmetic compositions for skin application. The declared nanoemulstion contains a water ingredient and a carrier which contains a lipophilic ingredient in the amount of 0.1-15 wt %, a surfactant and isopropyl and/or 1-propyl alcohol. The average emulsified particle diameter makes less than 100 nm. The method for preparing the nanoemulsion involves mixing the water ingredient and carrier containing the lipophilic ingredient, surfactant and isopropyl and/or 1-propyl alcohol, for preparing the nanoemulsion at temperature 50-60°C. The invention also refers to the composition for photodynamic therapy containing the above nanoemulsion and the active agent representing 5-aminolevulinic acid, a derivative, a precursor and/or a metabolite thereof. The above composition is applied to prepare the drug substance for photodynamic therapy and to treat senile keratosis. What is also declared is a diagnostic composition for detecting the dividing cells which contains the nanoemulsion and 5-aminolevulinic acid. The invention also refers to a kit for photodynamic therapy which comprises the composition for photodynamic therapy and one ingredient specified in a photoresist coating, an agent for attaching the above coating or an agent for applying the composition.EFFECT: invention provides better stability and intensified cell and tissue penetration of the nanoemulsion.25 cl, 6 dwg, 9 tbl, 5 ex

Using natural active substances in cosmetic or therapeutic compositions // 2491910
FIELD: medicine.SUBSTANCE: invention refers to cosmetology and represents a cosmetic composition containing: hydrolised yeast proteins as an active substance, and at least one acceptable carrier, differing by the fact that the above hydrolised yeast proteins are prepared by exogenic enzymatic hydrolysis and/or acid hydrolysis and/or alkaline hydrolysis of the yeast membranes.EFFECT: invention provides improved cosmetic activity, excellent time stability.17 cl, 6 ex, 3 tbl, 2 dwg

ethod for improving therapeutic efficacy of curcuminoids and analogues thereof // 2491084
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a method of increasing the therapeutic efficacy of curcuminoids and analogues thereof. The cosmetic method for uniform skin tanning for patients suffering psoriasis without hyperpigmentation comprising administering curcumine or its derivatives orally in a combination with exposure to ultraviolet under certain conditions. The cosmetic method for uniform skin tanning for patients suffering vitiligo without hyperpigmentation comprising administering curcumine or its derivatives orally in a combination with exposure to ultraviolet under certain conditions. Using the pharmaceutical composition comprising curcumin and its analogues applicable in treating psoriasis of a moderate to severe degree of severity in a combination with visible exposure under certain conditions.EFFECT: methods are effective for uniform skin tanning and psoriasis treatment.6 cl, 5 ex
Pharmaceutical composition for treating skin diseases and method for preparing it // 2489144
FIELD: medicine.SUBSTANCE: invention refers to medicine, and concerns a combined pharmaceutical composition for treating skin diseases. The composition contains betamethasone, preferentially betamethasone dipropionate, urea and at least one adjuvant. As adjuvants, the composition contains a hydrophobic component, an emulsifier, a preserving agent, a buffer agent, a non-aqueous solvent and water. A method for preparing the declared composition consists in the fact that the melted hydrophobic component, emulsifier and water are emulsified, and then betamethasone and the preserving agent are introduced at temperature below 60°C, homogenised and added with a prepared solution of urea and the buffer agent.EFFECT: pharmaceutical composition is characterised by high pharmacological activity, stability, uniform distribution of the active ingredients.7 cl, 8 ex, 1 tbl
ethod of treating guttate psoriasis // 2483762
FIELD: medicine.SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating guttate psoriasis. For this purpose, with underlying ointment therapy, the narrow-band medium-wave UV-radiation is applied at wave length 311 nm. That is preceded by prescribing Perfloxacin 400 mg twice a day for 5-7 days.EFFECT: method enables reducing a number of procedures, reducing a dose of the medium-wave UV-radiation, ensuring the faster clinical effect and prolonging the remission, arresting a comorbidity, reducing a probability of side effects and complications.2 ex, 1 tbl

1-aminoalkylcyclohexane derivatives for treatment of inflammatory skin diseases // 2481828
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of dermatology and represents application of 1-aminoalkylcyclohexane derivative, selected from neramexane and its pharmaceutically acceptable salts for treatment or prevention of inflammatory skin diseases, which represent acne, irritant dermatitis, impetigo and atopic dermatitis.EFFECT: invention ensures extension of arsenal of medications for treatment of inflammatory skin diseases.39 cl, 7 ex, 35 tbl, 5 dwg

Pyrimidine derivatives used as protein kinase inhibitors // 2478100
FIELD: medicine, pharmaceutics.SUBSTANCE: in formula (VIII): X represents NR7; Y represents O or N-(CH2)nR19; n is equal to 1 or 2; m is equal to 1 or 2; R1 represents H or C1-6alkyl; R2 independently represents H, C1-6alkyl or C5-6cycloalkyl; each of R4 and R4 independently represents H or C1-6alkyl; or R4 and R4 together form spiro-C3-6cycloalkyl group; R19 represents H, C1-6alkyl, C6aryl or C3cycloalkyl group; R6 represents OR8 ; and each of R7 and R8 independently represents H or C1-6alkyl. The invention also refers to compounds of formula VI, VII, a pharmaceutical composition containing said compounds, and a method of treating a proliferative disease, such as cancer.EFFECT: invention refers to new pyrimidine derivatives and their pharmaceutically acceptable salts possessing the properties of a PLK1 kinase inhibitor.24 cl, 8 tbl, 9 ex

Agent for neutralising toxic action of tumour necrosis factor on basis of hydrated pyrido(4,3-b)indoles, pharmacological agent on its basis and method of treating autoimmune disease on basis of neutralising toxic action of tumour necrosis factor // 2477131
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns an agent for neutralising toxic action of tumour necrosis factor on the basis of hydrated pyrido(4,3-b)indoles of formula (1), a pharmaceutical agent on the basis thereof, and a method of treating autoimmune diseases on the basis of neutralising toxic action of tumour necrosis factor.EFFECT: preparing the agent for treating autoimmune diseases on the basis of neutralising toxic action of tumour necrosis factor.13 cl, 1 tbl, 1 ex
ethod of treating psoriasis vulgaris // 2476228
FIELD: medicine.SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. That is ensured by a therapy involving a combination of the hepatoprotector Phosphogliv and an external non-hormonal therapy. Phosphogliv is prescribed according to the schedule: 2.5 mg intravenously once a day for 10 days, then orally 1 capsule 3 times a day; and the non-hormonal preparation is Cinocap cream 3 times a day; the therapeutic course makes 4 weeks.EFFECT: invention enables reducing a risk of complications and side effects and prolongs remission ensured by anti-inflammatory, hypolipidemic, immunomodulatory action of the prescribed preparations.
Agent for external therapy of chronic recurrent inflammatory dermatopathies // 2475249
FIELD: medicine.SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.4 ex
 
2551067.
Up!